{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:11:27Z","timestamp":1790626287224,"version":"4.1.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Pregabalin (PGL) is a gabapentinoid used to treat epilepsy, neuropathic pain and generalized anxiety disorder. PGL is also misused by heroin users as it enhances the effects of heroin. While it is thought those who misuse PGL take it in amounts greater than the recommended therapeutic dose, it is unknown whether there is a significant difference between the amounts of PGL used by heroin users compared to non-heroin users. This study hypothesized that the PGL concentrations in postmortem (PM) samples taken from heroin users positive for PGL would be higher than those in non-heroin users. Between 1 January 2016 and 31 December 2016, a routine drug screen and a specific screen for PGL were carried out on femoral-vein bloods from 3,750 PM Coroners\u2019 cases. Of the cases screened, 354 were heroin users, of which 264 cases were negative for gabapentinoids and therefore used as the control-heroin-user group. PGL was positive in 229 cases, of which 69 were heroin users and 160 were non-heroin users. On comparing the PGL concentrations, statistically higher concentrations were observed in the heroin users compared to non-heroin users (P\u2009=\u20090.002). There was no correlation between the concentrations of PGL and morphine (from heroin) in the heroin users (P\u2009=\u20090.95), and the amount of heroin (morphine) consumed was not dependant on whether PGL was consumed or not (P\u2009=\u20090.98). The prevalence of anti-depressants, benzodiazepines, methadone and non-heroin-related opioids was seen to be significantly higher in heroin users that were positive for PGL than the control-heroin users (P\u2009=\u2009&amp;lt;\u20090.001 for all drugs). This study suggests that heroin users are using greater amounts of PGL compared to non-heroin users; however, the magnitude of the difference in use may not be sufficient to conclude that heroin users are at substantially greater risk of PGL toxicity compared to non-heroin users. Results indicate that heroin users who take PGL are more likely to use multiple depressant drugs, hence increasing the risk of multi-drug toxicity and death in this population.<\/jats:p>","DOI":"10.1093\/jat\/bkab070","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T11:14:15Z","timestamp":1623237255000},"page":"471-478","source":"Crossref","is-referenced-by-count":8,"title":["Toxicological Relevance of Pregabalin in Heroin Users: A Two-Year Postmortem Population Study"],"prefix":"10.1093","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2491-9313","authenticated-orcid":false,"given":"Limon K","family":"Nahar","sequence":"first","affiliation":[{"name":"Toxicology Unit, Imperial College London, Charing Cross Campus, St. Dunstan\u2019s Road, London W6 8RP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Paterson","sequence":"additional","affiliation":[{"name":"Toxicology Unit, Imperial College London, Charing Cross Campus, St. Dunstan\u2019s Road, London W6 8RP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"2022052020440575700_R1","article-title":"Pregabalin","volume-title":"National Institute for Health and Care Excellence","author":"British National Formulary"},{"key":"2022052020440575700_R2","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1007\/s00228-013-1578-5","article-title":"Pregabalin abuse among opiate addicted patients","volume":"69","author":"Grosshans","year":"2013","journal-title":"European Journal of Clinical Pharmacology"},{"key":"2022052020440575700_R3","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1021\/jm049762l","article-title":"Structure\u2212 activity relationships of pregabalin and analogues that target the \u03b12-\u03b4 protein","volume":"48","author":"Belliotti","year":"2005","journal-title":"Journal of Medicinal Chemistry"},{"key":"2022052020440575700_R4","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1586\/14737175.7.7.769","article-title":"Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention","volume":"7","author":"Bandelow","year":"2007","journal-title":"Expert Review of Neurotherapeutics"},{"key":"2022052020440575700_R5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40263-014-0164-4","article-title":"Misuse and abuse of pregabalin and gabapentin: cause for concern?","volume":"28","author":"Schifano","year":"2014","journal-title":"CNS Drugs"},{"key":"2022052020440575700_R6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/bcp.12277","article-title":"Misuse of the \u03b3-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK","volume":"78","author":"Kapil","year":"2014","journal-title":"British Journal of Clinical Pharmacology"},{"key":"2022052020440575700_R7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000321079","article-title":"Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data","volume":"80","author":"Schifano","year":"2011","journal-title":"Psychotherapy and Psychosomatics"},{"key":"2022052020440575700_R8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.forsciint.2014.04.028","article-title":"Profiles of pregabalin and gabapentin abuse by postmortem toxicology","volume":"241","author":"H\u00e4kkinen","year":"2014","journal-title":"Forensic Science International"},{"key":"2022052020440575700_R9","article-title":"Further Down a Stony Road \u2013 Reporting on the DrugScope 2014 Street Drugs Survey","volume-title":"DrugWise","year":"2014"},{"key":"2022052020440575700_R10","article-title":"Advice for Prescribers on the Risk of the Misuse of Pregabalin and Gabapentin 2014","year":"2014"},{"key":"2022052020440575700_R11","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/jat\/bkz105","article-title":"An insight into gabapentin and pregabalin in Scottish prisoners","volume":"44","author":"Deeb","year":"2020","journal-title":"Journal of Analytical Toxicology"},{"key":"2022052020440575700_R12","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1111\/add.13843","article-title":"Risk to heroin users of polydrug use of pregabalin or gabapentin","volume":"112","author":"Lyndon","year":"2017","journal-title":"Addiction"},{"key":"2022052020440575700_R13","article-title":"The Pharmacological Effects of Diacetylmorphine (heroin) after Diffusion through the Blood-Brain Barrier","author":"Zovko","year":"2009"},{"key":"2022052020440575700_R14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.coph.2005.11.003","article-title":"The mechanisms of action of gabapentin and pregabalin","volume":"6","author":"Sills","year":"2006","journal-title":"Current Opinion in Pharmacology"},{"key":"2022052020440575700_R15","doi-asserted-by":"publisher","first-page":"732","DOI":"10.7326\/M18-1136","article-title":"Pregabalin and the risk for opioid-related death: a nested case\u2013control study","volume":"169","author":"Gomes","year":"2018","journal-title":"Annals of Internal Medicine"},{"key":"2022052020440575700_R16","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s40263-016-0359-y","article-title":"A decade of gabapentinoid misuse: an analysis of the European medicines agency\u2019s \u201cSuspected Adverse Drug Reactions\u201d database","volume":"30","author":"Chiappini","year":"2016","journal-title":"CNS Drugs"},{"key":"2022052020440575700_R17","article-title":"Deaths Related to Drug Poisoning by Selected Substances: 2019 Registrations","volume-title":"Office for National Statistics","year":"2020"},{"key":"2022052020440575700_R18","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jat\/bkz036","article-title":"Misuse and mortality related to gabapentin and pregabalin are being under-estimated: a two-year post-mortem population study","volume":"43","author":"Nahar","year":"2019","journal-title":"Journal of Analytical Toxicology"},{"key":"2022052020440575700_R19","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1007\/s00228-013-1578-5","article-title":"Pregabalin abuse among opiate addicted patients","volume":"69","author":"Grosshans","year":"2013","journal-title":"European Journal of Clinical Pharmacology"},{"key":"2022052020440575700_R20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11096-020-01222-x","article-title":"Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample","author":"Evoy","year":"2021","journal-title":"International Journal of Clinical Pharmacy"},{"key":"2022052020440575700_R21","first-page":"339","article-title":"Abuse of pregabalin\u2013results of the postmortem toxicology from 2010 to 2012","volume":"80","author":"Lottner-Nau","year":"2013","journal-title":"Toxichem Krimtech"},{"key":"2022052020440575700_R22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/1556-4029.13263","article-title":"Determining the toxicological significance of pregabalin in fatalities","volume":"62","author":"Elliott","year":"2017","journal-title":"Journal of Forensic Sciences"},{"key":"2022052020440575700_R23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jat\/bkz041","article-title":"Pregabalin and its involvement in coronial cases","volume":"44","author":"Thompson","year":"2020","journal-title":"Journal of Analytical Toxicology"},{"key":"2022052020440575700_R24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jchromb.2004.10.036","article-title":"Screening and semi-quantitative analysis of post mortem blood for basic drugs using gas chromatography\/ion trap mass spectrometry","volume":"813","author":"Paterson","year":"2004","journal-title":"Journal of Chromatography B"},{"key":"2022052020440575700_R25","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1258\/0004563001899744","article-title":"Analysis of urine for drugs of abuse using mixed-mode solid-phase extraction and gas chromatography-mass spectrometry","volume":"37","author":"Paterson","year":"2000","journal-title":"Annals of Clinical Biochemistry"},{"key":"2022052020440575700_R26","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.scijus.2010.09.005","article-title":"The United Kingdom and Ireland Association of Forensic Toxicologists: forensic toxicology laboratory guidelines (2010)","volume":"50","author":"Cooper","year":"2010","journal-title":"Science and Justice"},{"key":"2022052020440575700_R27","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/jat\/bkx019","article-title":"Validated method for the screening and quantification of baclofen, gabapentin and pregabalin in human post-mortem whole blood using protein precipitation and liquid chromatography\u2013tandem mass spectrometry","volume":"41","author":"Nahar","year":"2017","journal-title":"Journal of Analytical Toxicology"},{"key":"2022052020440575700_R28","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/jat\/bkv051","article-title":"Validated method for the quantification of buprenorphine in postmortem blood using solid-phase extraction and two-dimensional gas chromatography\u2013mass spectrometry","volume":"39","author":"Nahar","year":"2015","journal-title":"Journal of Analytical Toxicology"},{"key":"2022052020440575700_R29","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Therapeutic Drug Monitoring"},{"key":"2022052020440575700_R30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.0013-9580.2004.31203.x","article-title":"Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose\u2013response study in adults with partial seizures","volume":"45","author":"Arroyo","year":"2004","journal-title":"Epilepsia"},{"key":"2022052020440575700_R31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.forsciint.2016.05.033","article-title":"Pregabalin concentrations in post-mortem blood\u2014a two year study","volume":"266","author":"Eastwood","year":"2016","journal-title":"Forensic Science International"},{"key":"2022052020440575700_R32","volume-title":"Pregabalin. Disposition of Toxic Drugs and Chemicals in Man","author":"Baselt","year":"2014","edition":"10th"},{"key":"2022052020440575700_R33","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/jat\/bku004","article-title":"Quantification of pregabalin using hydrophilic interaction HPLC-high-resolution MS in postmortem human samples: eighteen case reports","volume":"38","author":"Priez-Barallon","year":"2014","journal-title":"Journal of Analytical Toxicology"},{"key":"2022052020440575700_R34","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/11536200-000000000-00000","article-title":"A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin","volume":"49","author":"Bockbrader","year":"2010","journal-title":"Clinical Pharmacokinetics"},{"key":"2022052020440575700_R35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02791072.2020.1861392","article-title":"Pregabalin misuse: motives, pattern, and knowledge about its risks among patients in methadone maintenance treatment","author":"Peles","year":"2020","journal-title":"Journal of Psychoactive Drugs"}],"container-title":["Journal of Analytical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jat\/advance-article-pdf\/doi\/10.1093\/jat\/bkab070\/42580667\/bkab070.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/46\/5\/471\/43773706\/bkab070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/46\/5\/471\/43773706\/bkab070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T20:44:22Z","timestamp":1653079462000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jat\/article\/46\/5\/471\/6296463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,6,10]]},"published-print":{"date-parts":[[2022,5,20]]}},"URL":"https:\/\/doi.org\/10.1093\/jat\/bkab070","relation":{},"ISSN":["0146-4760","1945-2403"],"issn-type":[{"value":"0146-4760","type":"print"},{"value":"1945-2403","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2021,6,10]]}}}